GLP-1 Drugs and Bowel Obstruction Risk: Evaluating a Safety Signal

Analysis of bowel obstruction and ileus events in GLP-1 drug users evaluates this safety signal using clinical data and pharmacovigilance reports.

Alfehaid, Lama et al.·Expert opinion on drug safety·2025·Strong EvidenceMeta-Analysis
RPEP-09855Meta AnalysisStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Meta-Analysis
Evidence
Strong Evidence
Sample
N=large
Participants
Adults taking GLP-1 receptor agonists across RCTs, cohort studies, and case reports

What This Study Found

Analysis of bowel obstruction and ileus events in GLP-1 drug users evaluates this safety signal using clinical data and pharmacovigilance reports.

Key Numbers

317 records screened. Meta-analysis included RCTs and observational studies. No statistically significant increase in bowel obstruction or ileus found.

How They Did This

Study design and methodology detailed in the full publication.

Why This Research Matters

These findings are relevant to the growing population of patients using or considering peptide-based therapies.

The Bigger Picture

This study contributes to the expanding evidence for peptide-based therapeutics in clinical medicine.

What This Study Doesn't Tell Us

Study limitations discussed in the full publication.

Questions This Raises

  • ?What are the long-term implications?
  • ?How do results compare to existing evidence?
  • ?What further research is needed?

Trust & Context

Key Stat:
Key finding Analysis of bowel obstruction and ileus events in GLP-1 drug users evaluates this safety signal usin
Evidence Grade:
Evidence assessment based on study design in publication.
Study Age:
Published in 2025.
Original Title:
Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.
Published In:
Expert opinion on drug safety, 1-9 (2025)
Database ID:
RPEP-09855

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Combines results from multiple studies to find an overall pattern.

What do these levels mean? →

Frequently Asked Questions

What does this study mean for patients?

Analysis of bowel obstruction and ileus events in GLP-1 drug users evaluates this safety signal using clinical data and pharmacovigilance reports.

How reliable are these findings?

Consult the full publication and your healthcare provider for personalized guidance.

Read More on RethinkPeptides

Cite This Study

RPEP-09855·https://rethinkpeptides.com/research/RPEP-09855

APA

Alfehaid, Lama; Alyami, Majed; Almohareb, Sumaya; Alshaya, Omar; Almutairi, Abdulaali. (2025). Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.. Expert opinion on drug safety, 1-9. https://doi.org/10.1080/14740338.2025.2465870

MLA

Alfehaid, Lama, et al. "Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.." Expert opinion on drug safety, 2025. https://doi.org/10.1080/14740338.2025.2465870

RethinkPeptides

RethinkPeptides Research Database. "Evaluating bowel obstruction and ileus events in patients on..." RPEP-09855. Retrieved from https://rethinkpeptides.com/research/alfehaid-2025-evaluating-bowel-obstruction-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.